company background image
300558 logo

Betta Pharmaceuticals SZSE:300558 Stock Report

Last Price

CN¥32.01

Market Cap

CN¥13.2b

7D

2.7%

1Y

-38.3%

Updated

22 Jul, 2024

Data

Company Financials +

Betta Pharmaceuticals Co., Ltd.

SZSE:300558 Stock Report

Market Cap: CN¥13.2b

300558 Stock Overview

Researches and develops, manufactures, and markets medicines for the treatment of cancer in China.

300558 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance3/6
Financial Health3/6
Dividends1/6

Betta Pharmaceuticals Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Betta Pharmaceuticals
Historical stock prices
Current Share PriceCN¥32.01
52 Week HighCN¥63.09
52 Week LowCN¥30.43
Beta0.70
11 Month Change-10.56%
3 Month Change-17.18%
1 Year Change-38.31%
33 Year Change-64.77%
5 Year Change-32.02%
Change since IPO26.52%

Recent News & Updates

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Jul 05
These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Recent updates

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Jul 05
These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Apr 26
Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Apr 23
Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Apr 16
What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Shareholder Returns

300558CN PharmaceuticalsCN Market
7D2.7%1.1%0.2%
1Y-38.3%-13.1%-16.6%

Return vs Industry: 300558 underperformed the CN Pharmaceuticals industry which returned -13.1% over the past year.

Return vs Market: 300558 underperformed the CN Market which returned -16.6% over the past year.

Price Volatility

Is 300558's price volatile compared to industry and market?
300558 volatility
300558 Average Weekly Movement5.1%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement5.9%
10% most volatile stocks in CN Market9.1%
10% least volatile stocks in CN Market3.9%

Stable Share Price: 300558's share price has been volatile over the past 3 months.

Volatility Over Time: 300558's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20032,000Lieming Dingwww.bettapharma.com

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. The company was founded in 2003 and is headquartered in Hangzhou, China.

Betta Pharmaceuticals Co., Ltd. Fundamentals Summary

How do Betta Pharmaceuticals's earnings and revenue compare to its market cap?
300558 fundamental statistics
Market capCN¥13.22b
Earnings (TTM)CN¥394.78m
Revenue (TTM)CN¥2.66b

33.9x

P/E Ratio

5.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300558 income statement (TTM)
RevenueCN¥2.66b
Cost of RevenueCN¥454.77m
Gross ProfitCN¥2.21b
Other ExpensesCN¥1.81b
EarningsCN¥394.78m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 06, 2024

Earnings per share (EPS)0.94
Gross Margin82.91%
Net Profit Margin14.84%
Debt/Equity Ratio44.2%

How did 300558 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

18%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.